课题基金 / 基金详情

Bioresorbable Polythioketal Urethane Wound Dressings

Bioresorbable Polythioketal Urethane Wound Dressings
生物可吸收聚硫缩酮聚氨酯伤口敷料
批准号:
10734630
负责人:
Craig Lewis Duvall
金额:
$58.35万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
未结题
起止时间:
2014-09-25 至 2027-07-31
关键词:
AccelerationAddressAdmission activityAnimal ModelBecaplerminBenchmarkingBiocompatible MaterialsBiomedical EngineeringCarbon DioxideCattleCellsCellular InfiltrationCelluloseCessation of lifeChemistryClinicalCollaborationsCollagenCouplesCrosslinkerDataDevicesDiabetes MellitusEngineeringEquilibriumExcisionFDA approvedFamily suidaeFormulationGene ExpressionGenerationsGlycolsGlycosaminoglycansGoalsGranulation TissueHealth Care CostsHealthcare SystemsHistologicHistopathologyHospitalsHydrolysisHydrophobicityHydroxyl RadicalImmuneImmunologicsImmunologyIncidenceInfiltrationIschemiaIsocyanatesKineticsLeadLegal patentLengthLibrariesModelingMorbidity - disease rateNatureNon-Insulin-Dependent Diabetes MellitusOutcomePathologicPhenotypePlatelet-Derived Growth FactorPolyestersPolymersPolyurethanesPorosityProcessProcollagen-Proline DioxygenasePropertyPublicationsPublishingReactionReactive Oxygen SpeciesRecombinantsSeriesSideSiliconesSilverSiteSkinSmall Interfering RNASourceSterile coveringsTechnologyTestingTimeTissuesTranslational ResearchUrethaneVariantVertebral columnWaterWorkWound InfectionWound modelsadaptive immune responseaging populationchronic woundclinical applicationclinical developmentclinically relevantcostcrosslinkdensitydesigndiabeticdiabetic patientdiabetic ratdiabetic ulcerethylene glycolfabricationhealinghydrophilicityimmunogenicimmunogenicityin vivoinnovationinventionlead candidatelimb amputationmanufacturemechanical propertiesmultidisciplinarynanoparticlenext generationnovelpolyurethane foampre-clinicalprismarepairedresponsescaffoldscreeningskin woundsuccesstimelinetissue repairtranslational medicinewoundwound carewound dressingwound healing

项目摘要

项目成果

Craig Lewis Duvall的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT Nonhealing skin wounds are a major source of morbidity worldwide and becoming more of a burden due to an increase in health care costs, an aging population, and growing incidence of diabetes. Non-healing skin wounds occur in nearly 25% of diabetic patients, and ~6% are admitted to the hospital for wound-related treatment, which if not successful, can lead to limb amputation or death. More advanced treatments such as synthetic, resorbable dressings that are placed into the wound to provide a scaffolding for cell infiltration and new tissue formation have started to gain clinical impact. However, currently available polymeric biomaterial wound dressings degrade by hydrolysis, releasing acidic byproducts, creating an autocatalytic degradation process. This can lead to inconsistent degradation rate over time and poor matching between the timeline of cell infiltration / new tissue formation and the timeline of polymeric scaffold resorption. The overall goal of the current project is to develop and apply a next generation cellular reactive oxygen species (ROS) degradable, fully synthetic foam wound dressing. These scaffolds are formed by the reaction of ROS-degradable polythioketal (PTK) diols with isocyanate-containing compounds in the presence of a small quantity of water. This generates a crosslinked polyurethane (resultant bond from reaction of isocyanate and hydroxyl) network that is highly porous in nature due to CO2 generation via the blowing reaction between isocyanates and water. The properties of the resultant polythioketal urethane (PTK-UR) foams can be tuned based on the composition of the PTK diol crosslinker which makes up the bulk of the foam. We propose to develop a library of PTK diols with controlled variation in degree of hydrophilicity, consistent density of thioketal bonds in the backbone, and low potential for immunogenicity. This plan is based on highly- promising preliminary data that PTK-UR scaffold hydrophilicity is a critical factor in the wound healing response to the PTK-UR biomaterials. The proposed polymer series will fill previous gaps in our previous work by yielding a well-controlled, highly-scalable chemistry for better fine tuning of PTK-UR hydrophobic/hydrophilic balance across a broad range with diol chemistries that are not based on potentially immunogenic PEG. The aims of the project will involve synthesis and screening of this new class of thioketal diols, benchmarking of the leading PTK- UR formulations against clinical products for wound healing efficacy, and application of lead PTK-UR formulations for cargo delivery to promote healing in the context of pathological (infected and diabetic) wounds. Our multidisciplinary team includes bioengineers, polymer and polyurethane material chemists, preclinical wound healing model and histopathology expertise, expertise in immunology of wound healing / skin wound infection, and clinical wound care. This group is poised to achieve the proposed goals toward establishing a new clinically impactful, cell-resorbable, synthetic polymer-based foam wound dressing.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.addr.2014.12.006
发表时间: 2015-07-01
期刊: ADVANCED DRUG DELIVERY REVIEWS
影响因子: 16.1
作者: [Beavers, Kelsey R., Nelson, Christopher E., Duvall, Craig L.]
通讯作者: Duvall, Craig L.
DOI: 10.1002/jbm.a.35413
发表时间: 2015-09
期刊: Journal of biomedical materials research. Part A
影响因子: --
作者: [Sarett SM, Kilchrist KV, Miteva M, Duvall CL]
通讯作者: Duvall CL
DOI: 10.1016/j.actbio.2021.01.013
发表时间: 2021-04-01
期刊: Acta biomaterialia
影响因子: 9.7
作者: [McMillan A, Nguyen MK, Huynh CT, Sarett SM, Ge P, Chetverikova M, Nguyen K, Grosh D, Duvall CL, Alsberg E]
通讯作者: Alsberg E
DOI: 10.1016/j.jconrel.2015.09.066
发表时间: 2015-11-28
期刊: Journal of controlled release : official journal of the Controlled Release Society
影响因子: --
作者: [Sarett SM, Nelson CE, Duvall CL]
通讯作者: Duvall CL
7
    Next Gen Targeted nanoparticles for Inhibiting Gli2 in Bone Metastatic Tumors
    Tissue Adhesive RNA Interference Nanoparticles to Block Progression of Posttraumatic and Spontaneous Osteoarthritis.
    • 批准号:
      10539405
    • 项目类别:
    • 资助金额:
      $62.21万
    • 财政年份:
      2022
    • 负责人:
      Craig Lewis Duvall
    • 依托单位:
    Tissue Adhesive RNA Interference Nanoparticles to Block Progression of Posttraumatic and Spontaneous Osteoarthritis.
    • 批准号:
      10688080
    • 项目类别:
    • 资助金额:
      $54.32万
    • 财政年份:
      2022
    • 负责人:
      Craig Lewis Duvall
    • 依托单位:
    Albumin hitchhiking siRNAs for gene targeting in aged brain
    • 批准号:
      10611521
    • 项目类别:
    • 资助金额:
      $19.0万
    • 财政年份:
      2022
    • 负责人:
      Craig Lewis Duvall
    • 依托单位:
    海外基金